Want to see SANA full AI Analyst Report?
SANA Stock Chart & Stats
$3.52
$3.38(204.85%)
At close: 4:00 PM EST
$3.52
$3.38(204.85%)
Day’s Range― - ―
52-Week Range$2.61 - $6.55
Previous CloseN/A
Volume118.31M
Average Volume (3M)2.43M
Market Cap
$876.62M
Enterprise Value$767.34
Total Cash (Recent Filing)$101.14M
Total Debt (Recent Filing)$75.33M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Jul 30, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding278,291,600
10 Day Avg. Volume3,390,584
30 Day Avg. Volume2,429,628
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)6.41
Price to Sales (P/S)0.00
P/FCF Ratio-7.12
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.80Price Target Upside178.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Validation (HIP-modified Cells)A peer-reviewed NEJM letter reporting 14-month follow-up for HIP-modified islet transplants provides durable external validation of Sana’s hypoimmune platform. This recognition strengthens translational credibility, supports SC451 development plans and can materially de-risk the program as it moves into Phase 1/2.
Narrowing Operating LossesImprovement in operating losses over multiple years indicates better cost control and program prioritization. Sustained narrowing reduces future funding requirements, enhances runway prospects, and signals management ability to tighten spend while advancing key R&D priorities—an important structural improvement.
Recent Financings Bolstered RunwayThe ~$69M equity raise plus a strategic investment option materially extend near-term liquidity and support development through 2027. While equity funding is dilutive, securing committed capital and strategic partners increases the firm’s ability to execute multi-year clinical plans and reduces immediate solvency risk.
Bears Say
No Product RevenueAbsence of recurring product revenue means the business lacks internal cash generation and remains wholly dependent on external funding or partnerships. This structural absence of commercial income raises execution risk and prolongs reliance on capital markets until commercialization or out-licensing occurs.
Persistent Negative Free Cash FlowConsistent negative operating and free cash flow show the company converts R&D spending into real cash burn, not just non-cash charges. Even with improvement from prior years, this ongoing outflow necessitates continual financing and limits strategic flexibility for scale-up or unexpected setbacks over the medium term.
Sharp Equity ErosionSteep decline in shareholders' equity reduces the company’s financial buffer and increases the dilutive impact of future capital raises. A weakened balance sheet limits optionality for large investments (e.g., manufacturing scale-up) and amplifies the adverse effects of additional adverse trial outcomes or delays.
Sana Biotechnology News
SANA FAQ
What was Sana Biotechnology’s price range in the past 12 months?
Sana Biotechnology lowest stock price was $2.61 and its highest was $6.55 in the past 12 months.
What is Sana Biotechnology’s market cap?
Sana Biotechnology’s market cap is $876.62M.
When is Sana Biotechnology’s upcoming earnings report date?
Sana Biotechnology’s upcoming earnings report date is Jul 30, 2026 which is in 10 days.
How were Sana Biotechnology’s earnings last quarter?
Sana Biotechnology released its earnings results on May 11, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.162 by -$0.008.
Is Sana Biotechnology overvalued?
According to Wall Street analysts Sana Biotechnology’s price is currently Undervalued.
Does Sana Biotechnology pay dividends?
Sana Biotechnology does not currently pay dividends.
What is Sana Biotechnology’s EPS estimate?
Sana Biotechnology’s EPS estimate is -0.15.
How many shares outstanding does Sana Biotechnology have?
Sana Biotechnology has 278,291,600 shares outstanding.
What happened to Sana Biotechnology’s price movement after its last earnings report?
Sana Biotechnology reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.162. Following the earnings report the stock price went down -8.427%.
Which hedge fund is a major shareholder of Sana Biotechnology?
Currently, no hedge funds are holding shares in SANA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sana Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.80 (178.41% Upside)
$9.80 (178.41% Upside)
Hedge Fund Trend
Increased
By 2.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
37.61%
12-Months-Change
Fundamentals
Return on Equity
-161.87%
Trailing 12-Months
Asset Growth
-16.14%
Trailing 12-Months
Company Description
Sana Biotechnology
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
SANA Stock 12 Month Forecast
Average Price Target
$9.80
▲(178.41% Upside)
Technical Analysis
Geron
―
Editas Medicine
―
Crispr Therapeutics AG
―
Taysha Gene Therapies
―
Prime Medicine, Inc.
―
Ownership Overview
14.60% Insiders
11.74% Mutual Funds
0.01% Other Institutional Investors
62.95% Public Companies and
Individual Investors